Drawing for ALIGATER

USPTO serial 50052128

ALIGATER

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
—
Law office
—

What this means

Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies. Wait for assignment and the first examiner action. Monitor TSDR monthly for status changes to 638 (assigned) or an office action.

Status 630: Status 630 means your trademark application is in the USPTO queue and has not yet been assigned to an examining attorney. This is normal shortly after filing. Examination typically begins within three to four months, though timing varies.

Need help with ALIGATER?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Pina Campagna

Pina Campagna Carter, Deluca, & Farrell, LLP576 Broad Hollow Rd.Melville, NY 11747United States

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations in the form of viral systems, gene therapy systems, viral vectors and gene therapy vectors, namely, chemically conjugated viral systems and viral vectors, DNA viruses such as adeno-associated viruses (AAVs) for the treatment of ophthalmic disorders, diseases of the central and peripheral nervous systems, hereditary disorders, genetic disorders and monogenic disorders; Pharmaceutical preparations containing viral vectors for gene therapy; Medicinal preparations for medical, pharmaceutical or veterinary use comprising conjugated viral systems and viral vectors for the treatment of ophthalmic disorders, diseases of the central and peripheral nervous systems, hereditary disorders, genetic disorders and monogenic disorders; Chemical reagents for medical purposes; Chemical reagents for veterinary purposes; Biological reagents for medical purposes; Biological reagents for veterinary purposes; Pharmaceutical preparations for cellular therapy for the treatment of ophthalmic disorders, diseases of the central and peripheral nervous systems, hereditary disorders, genetic disorders and monogenic disorders; Therapeutic biological preparations for use in targeted medical and clinical gene therapy, namely, for ophthalmic disorders, diseases of the central and peripheral nervous systems, hereditary disorders, genetic disorders and monogenic disorders, comprising conjugated viral systems and viral vectors; Biological preparations for use in cell cultures for medical purposesACTIVE—
042Research and development in the field of biotechnology and targeted gene therapy, namely, research and development based on a platform for the discovery, identification and manufacture of viral systems and vectors chemically conjugated with various types of functional ligands, namely, DNA viruses such as adeno-associated viruses (AAVs); Biological research in the field of conjugated viral systems and viral vectors, targeted gene therapy systems and nucleic acid delivery systems based on conjugated viral systems and viral vectors; Biomedical research in the field of conjugated viral systems and viral vectors, targeted gene therapy systems and nucleic acid delivery systems based on conjugated viral systems and viral vectors; Pharmaceutical research in the field of conjugated viral systems and viral vectors, targeted gene therapy systems and nucleic acid delivery systems based on conjugated viral systems and viral vectors; Research and development in the field of pharmaceuticals relating to conjugated viral systems and viral vectorsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 27, 2026NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 14, 2026MAFRAPPLICATION FILING RECEIPT MAILED—
Aug 14, 2026NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance